Go Pro
NASDAQ:ACON

Aclarion Q2 2026 Earnings Report

Aclarion logo
$2.38 -0.06 (-2.46%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$2.37 -0.01 (-0.34%)
As of 10/2/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclarion EPS Results

Actual EPS
-$1.12
Consensus EPS
-$1.05
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Aclarion Revenue Results

Actual Revenue
$0.03 million
Expected Revenue
$0.03 million
Beat/Miss
Missed by -$4.79 thousand
YoY Revenue Growth
N/A

Aclarion Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Aclarion's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Aclarion Earnings Headlines

Health Catalyst (NASDAQ:HCAT) and Aclarion (NASDAQ:ACON) Critical Analysis
Aclarion (NASDAQ:ACON) versus Veeva Systems (NYSE:VEEV) Financial Analysis
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
See More Aclarion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email.

About Aclarion

Aclarion (NASDAQ:ACON) (NASDAQ: ACON) is a healthcare technology company focused on improving the diagnosis and treatment of chronic low back pain. The company develops tools intended to help physicians identify the spinal discs that may be contributing to a patient’s pain and support more informed treatment decisions.

Its principal product, Nociscan, is a cloud-based platform that analyzes data from magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI). By combining imaging information with proprietary algorithms and biochemical biomarkers, the platform is designed to provide physicians with additional objective information about disc health and potential pain generators.

Aclarion was formerly known as Nocimed and adopted the Aclarion name as it expanded its focus on data-driven spine care. The company markets its technology to healthcare providers and spine specialists in the United States and internationally. Its solutions are intended to complement, rather than replace, clinical evaluation and existing diagnostic imaging.

View Aclarion Profile